UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported): June 16, 2021
GB Sciences, Inc.
(Exact name of Registrant as specified in its charter)
Nevada
(State or other Jurisdiction of
Incorporation or organization)
|
000-55462
(Commission File Number)
|
59-3733133
(IRS Employer I.D. No.)
|
3550 W. Teco Avenue
Las Vegas, NV 89118
(Address of Principal Executive Offices) (Zip Code)
(844) 843-2569
Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR
240. l 4a- l 2)
☐
Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
None
|
N/A
|
N/A
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Resignation and Appointment of Certain
Officers.
Effective June 16, 2021, the board of directors (the “Board”) of
the registrant (the “Company”) appointed Dr. Andrea Small-Howard
President of the Company. Also, effective June 16, 2021, John
Poss resigned his position as President, allowing for the
appointment of Dr. Small-Howard. Mr. Poss will continue to
serve as Chief Executive Officer and as Chairman of the Board of
Directors. Dr. Small-Howard will also continue to serve as
the Company’s Chief Science Officer.
Dr. Small-Howard was appointed as the Chief Science Officer and as
a member of our board of directors on June 10, 2014, and she has
served continuously in both positions since that time. As the Chief
Science Officer, Dr. Small-Howard’s goal has been to create and
maintain a novel plant-inspired therapy pipeline based on the
Company's proprietary in silico technology suite, direct
research & development efforts, facilitate research and
development partnerships, guide product commercialization
strategies, develop corporate messaging around our novel drug
discovery process, and make public presentations promoting the
Company’s drug development programs and unique corporate
strategy.
Dr. Andrea Small-Howard has more than 20 years of research
experience; as well as executive experience in the
biopharmaceutical industry supervising research and development,
manufacturing, and quality control divisions in both the US and
China. In her biotechnology career, Dr. Small-Howard has taken
novel biological products from ideation through commercialization.
Dr. Small-Howard has been named an inventor on more than sixty
patent applications and taken the lead in obtaining regulatory
approvals from the U.S. Food and Drug Administration ("US FDA") and
numerous international regulatory agencies. Dr. Small-Howard also
created commercialization strategies, advised on distribution
relationships, led branding committees, and supervised marketing
materials. In one instance, Dr. Small-Howard designed a
commercialization strategy for an in-licensed cervical cancer test.
To that end, she developed technical product files in Korea with
the original manufacturer, sourced US raw materials, hired contract
manufacturers, created the US prototypes, and prepared regulatory
filings. As VP of Scientific Oversight at Radient Pharmaceuticals
Corp., she provided strategic product development and regulatory
oversight across multiple international business divisions.
Dr. Small-Howard has directed research efforts on cannabinoids for
over 20 years, leading a project group dedicated to the study of
cannabinoids in the immune system as an NIH-funded post-doctoral
fellow. In this work, she published one of the earliest studies of
cannabinoid impacts on pro-inflammatory immunocytes. More recently
she has contributed to published studies on consumer protection
issues surrounding ‘medicinal’ Cannabis chemovars in Nevada,
co-authored scholarly reviews on cannabinoids in heart disease and
Parkinson’s disease, co-authored mechanistic studies on cannabinoid
and terpene regulation of ion channels, and co-authored an
innovative study demonstrating the utility of nanoparticles as
delivery vehicles for Cannabis-derived therapeutic compounds.
For a four-year term (2012-2016), Dr. Small-Howard served on the
Board of Directors for the Center for Healthcare Innovation, a
nonprofit, non-partisan, and independent organization based in
Chicago that is committed to serving as a catalyst for stimulating
ideas, people, companies, and institutions to collaborate and
achieve excellence in healthcare innovation. Her board level
responsibilities at CHI included shaping and supporting the
evolving mission of this dynamic group. She also served on the
planning committee for their annual "Emerging Markets in the Life
Sciences" seminar series, which ran for 5 years.
From July 2011 to June 2014, Dr. Small-Howard was the Founder and
President of International Biotechnology Solutions, a management
consulting firm that created customized, cost-effective
commercialization solutions for viable yet abandoned
biopharmaceutical products. International Biotechnology Solutions
provided management consulting with a focus on assisting US biotech
companies with products that could be commercialized within the
Asia-Pacific region. Dr. Small-Howard successfully completed
projects within the areas of business development, corporate
alliance building, product commercialization, due diligence
reporting on medical marijuana companies, corporate restructuring,
and management of successful fund-raising campaigns.
From June 2011 to March 2013, she served as a Director on the Board
of Directors (President for part of that time), for the Ceremax
Investment Corporation. The Ceremax Investment Group was
established by members of the USC EMBA Class XXV to pool its
financial and intellectual resources to identify investment
opportunities. During her tenure at Ceremax, Dr. Small Howard
reviewed and approved capital and resource investments in promising
start-up or scale-up phase private companies.
From November, 2008 to July, 2011, Dr. Small-Howard served as the
Vice President of Scientific Oversight for the Radient
Pharmaceutical Corporation, a vertically-integrated
biopharmaceutical research, development, and manufacturing
corporation with operations in both the US and China. Dr.
Small-Howard provided oversight for global product development in
multiple international business divisions. She authored and/or
attained 12 patents & 3 trademarks on proprietary cancer tests,
cancer (gene) therapies, cosmeceuticals, and novel animal models.
She achieved numerous regulatory approvals for cancer tests, cancer
therapies, pharmaceuticals, and cosmeceutical products with the
United States FDA, Health Canada, and other foreign ministries of
health. She initiated and/or nurtured five international,
collaborative, cancer research trial programs with universities
that yielded 7 publications supporting cancer products and
supervised the Quality Management Systems for an ISO 13485/cGMP
compliant medical device manufacturing facility in the US; as well
as the regulated manufacturing facilities in China. She also led
and participated in internal and US FDA, CDPH, CE Mark/ISO 13485,
and CMDR audits of Radient’s Quality Management System.
SIGNATURE PAGE
Pursuant to the requirement of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
GB
Sciences, Inc.
a
Nevada corporation
|
|
|
|
|
|
|
Dated: June 16, 2021
|
|
By:
|
/s/ John Poss
|
|
|
|
|
John Poss
|
|
|
|
|
Chief Executive Officer
|
|
GB Sciences (QB) (USOTC:GBLX)
Historical Stock Chart
From Apr 2022 to May 2022
GB Sciences (QB) (USOTC:GBLX)
Historical Stock Chart
From May 2021 to May 2022